{"id":9867,"date":"2026-05-30T13:24:11","date_gmt":"2026-05-30T13:24:11","guid":{"rendered":"https:\/\/www.healthoptibody.com\/?p=9867"},"modified":"2026-05-30T13:24:11","modified_gmt":"2026-05-30T13:24:11","slug":"weight-loss-drugs-are-reshaping-the-brain-to-dull-peoples-desire-for-food-alcohol-and-even-sex-study-suggests","status":"publish","type":"post","link":"https:\/\/www.healthoptibody.com\/?p=9867","title":{"rendered":"Weight-loss drugs are reshaping the brain to dull people&#8217;s desire for food, alcohol and even sex, study suggests"},"content":{"rendered":"<p><\/p>\n<div itemprop=\"articleBody\">\n<p class=\"mol-para-with-font\">People taking Ozempic and other blockbuster weight loss drugs expect them to curb their appetite and help them <a style=\"font-weight: bold;\" target=\"_self\" href=\"https:\/\/www.dailymail.com\/news\/weight_loss\/index.html\" id=\"mol-5e589e10-5b60-11f1-b4d8-23827a91940c\" class=\"\">lose weight<\/a>.<\/p>\n<p class=\"mol-para-with-font\">GLP-1 agonists, which include Ozempic and also Wegovy and Mounjaro, mimic glucagon-like peptide-1 (GLP-1), a naturally present hormone in the gut that slows digestion, regulates blood sugar and tells the body it&#8217;s full &#8211; which helps control <a style=\"font-weight: bold;\" target=\"_self\" href=\"https:\/\/www.dailymail.com\/health\/diabetes\/index.html\" id=\"mol-798709b0-5b6a-11f1-a786-49fc118f1e30\">diabetes<\/a> and weight.\u00a0<\/p>\n<p class=\"mol-para-with-font\">This directly stops a user&#8217;s appetite in its tracks and causes them to eat smaller portions.\u00a0<\/p>\n<p class=\"mol-para-with-font\">The drugs were originally developed for type 2 diabetes, and have become famous in recent years for helping to control obesity, but new research shows the drugs also do something else remarkable: they could actually rewire the human brain.<\/p>\n<p class=\"mol-para-with-font\">In a new study, researchers at the University of <a style=\"font-weight: bold;\" target=\"_self\" href=\"https:\/\/www.dailymail.com\/news\/virginia\/index.html\" id=\"mol-5e5b0f10-5b60-11f1-b4d8-23827a91940c\" class=\"\">Virginia<\/a>\u00a0found a new generation of oral GLP-1s can directly influence brain circuits tied to reward and motivation, as well as hunger.\u00a0<\/p>\n<p class=\"mol-para-with-font\">This means the drugs may reshape the brain&#8217;s desire for food itself, along with appetite, which could help explain the drugs&#8217; effectiveness, <a style=\"font-weight: bold;\" target=\"_self\" class=\"\" href=\"https:\/\/www.dailymail.com\/health\/article-15356791\/weight-loss-ozempic-wegovy-chronic-cough.html\">as well as side effects<\/a>\u00a0like nausea and stomach discomfort and losing interest in vices like sex, gambling and <a style=\"font-weight: bold;\" target=\"_self\" href=\"https:\/\/www.dailymail.com\/news\/alcohol\/index.html\" id=\"mol-cc7aba60-5b81-11f1-8181-3be97cbe424f\">alcohol<\/a>.\u00a0<\/p>\n<p class=\"mol-para-with-font\">&#8216;This is just the beginning,&#8217; Dr Ali D. G\u00fcler, lead study author and neuroscientist at the University of Virginia said. &#8216;If we understand these pathways, we may be able to design treatments that target specific behaviors \u2014 whether that\u2019s overeating, addiction or something else entirely.<\/p>\n<p class=\"mol-para-with-font\">&#8216;If these drugs are affecting reward pathways in the brain, that has implications beyond weight loss. It could influence things like addiction, impulse control or even how people experience pleasure.&#8217;<\/p>\n<div class=\"artSplitter mol-img-group\" style=\"\">\n<div class=\"mol-img\">\n<div class=\"image-wrap\"> <img loading=\"lazy\" decoding=\"async\" id=\"i-17e6ad521a4f967d\" src=\"https:\/\/i.dailymail.com\/1s\/2026\/05\/29\/17\/108959743-15858713-A_new_study_found_GLP_1_medications_like_Ozempic_and_Wegovy_may_-a-2_1780072084982.jpg\" height=\"425\" width=\"634\" alt=\"A new study found GLP-1 medications like Ozempic and Wegovy may alter pathways in the brain (file photo)\" class=\"blkBorder img-share\" style=\"max-width:100%\" loading=\"lazy\" \/> <\/div>\n<\/p><\/div>\n<p class=\"imageCaption\">A new study found GLP-1 medications like Ozempic and Wegovy may alter pathways in the brain (file photo)<\/p>\n<\/div>\n<p><iframe data-xpmodule-iframe-resizable=\"\" scrolling=\"no\" name=\"xp-iframe-mpsdtn4tx0y1ud3bqej\" class=\"iframe-creator \" src=\"https:\/\/i.dailymail.co.uk\/i\/html_modules\/Annie\/tests\/240905-healthsubheading-finalversion\/index.html\" allow=\"clipboard-write\" height=\"45\" style=\"border: 0; width: 0; min-width: 100%; \" id=\"xp-iframe-mpsdtn4tx0y1ud3bqej\"><\/p>\n<p>Your browser does not support iframes.<\/p>\n<p>    <\/iframe><\/p>\n<p class=\"mol-para-with-font\">While the study focused on mouse models, the researchers believe the findings could offer important clues as to how specific GLP-1 formulations act on the human brain.\u00a0<\/p>\n<p class=\"mol-para-with-font\">&#8216;These drugs are incredibly effective,&#8217; G\u00fcler said.\u00a0&#8216;But what we wanted to understand is what they\u2019re doing in the brain.&#8217;<\/p>\n<p class=\"mol-para-with-font\">The findings come as about one in eight US adults &#8211; around 31 million &#8211; report they have taken GLP-1 medications like Ozempic, Wegovy and Mounjaro at least once.\u00a0<\/p>\n<p class=\"mol-para-with-font\">The CDC also estimates three in four Americans are overweight or obese, and over 36 million are living with type 2 diabetes.<\/p>\n<p class=\"mol-para-with-font\">The new study, published in <a style=\"font-weight: bold;\" target=\"_blank\" class=\"\" rel=\"nofollow\" href=\"https:\/\/www.nature.com\/articles\/s41586-026-10444-4\">Nature<\/a>, looked at mice that were genetically engineered so their brains&#8217; GLP-1 receptors closely resembled those found in humans.\u00a0<\/p>\n<p class=\"mol-para-with-font\">The team used the mice to test the drugs\u00a0danuglipron and orforglipron (marketed as Foundayo), which are oral GLP-1 agonists developed by Pfizer and Eli Lilly, respectively.\u00a0<\/p>\n<p class=\"mol-para-with-font\">Pfizer discontinued the development of danuglipron last year due to one asymptomatic study participant developing a potential drug-induced liver injury. It&#8217;s unclear if the company will pursue further studies on the drug.\u00a0<\/p>\n<p class=\"mol-para-with-font\">The experts note past studies have shown these newer generation GLP-1s act on neurons in the hindbrain, a region that helps control feelings of fullness and nausea.\u00a0<\/p>\n<p class=\"mol-para-with-font\">The team found in addition to those effects, the drugs also engage a separate circuit linking the hindbrain to the central amygdala, a structure that processes emotions and neurons that produce dopamine, a &#8216;feel-good&#8217; neurotransmitter that controls the body&#8217;s reward system.\u00a0<\/p>\n<p class=\"mol-para-with-font\">Activating that pathway reduces the release of dopamine, helping to cut cravings and compulsive overeating.\u00a0\u00a0<\/p>\n<div class=\"artSplitter mol-img-group\" style=\"\">\n<div class=\"mol-img\">\n<div class=\"image-wrap\"> <img loading=\"lazy\" decoding=\"async\" id=\"i-5169a51b0e97c283\" src=\"https:\/\/i.dailymail.com\/1s\/2026\/05\/29\/17\/108644827-15858713-The_new_study_found_GLP_1_drugs_may_dampen_dopamine_which_contro-a-1_1780072084981.jpg\" height=\"426\" width=\"634\" alt=\"The new study found GLP-1 drugs may dampen dopamine, which controls the body's reward system (stock image)\" class=\"blkBorder img-share\" style=\"max-width:100%\" loading=\"lazy\" \/> <\/div>\n<\/p><\/div>\n<p class=\"imageCaption\">The new study found GLP-1 drugs may dampen dopamine, which controls the body&#8217;s reward system (stock image)<\/p>\n<\/div>\n<p><iframe data-xpmodule-iframe-resizable=\"\" scrolling=\"no\" name=\"xp-iframe-mpsdpznwgfs54c3ihoo\" class=\"iframe-creator \" src=\"https:\/\/i.dailymail.co.uk\/i\/html_modules\/2026\/01_JAN\/262201_cheaper-ozempic\/index.html\" allow=\"clipboard-write\" height=\"400\" style=\"border: 0; width: 0; min-width: 100%; \" id=\"xp-iframe-mpsdpznwgfs54c3ihoo\"><\/p>\n<p>Your browser does not support iframes.<\/p>\n<p>    <\/iframe><\/p>\n<p class=\"mol-para-with-font\">G\u00fcler also notes this pathway plays a critical role in the brain assigning value to rewarding experiences like eating high-calorie foods.\u00a0<\/p>\n<p class=\"mol-para-with-font\">And past research shows GLP-1 users can lose interest in addictive or pleasurable behaviors, such as sex, alcohol and gambling, so the study may shed light on these unexpected side effects.\u00a0<\/p>\n<p class=\"mol-para-with-font\">&#8216;What we show is that these drugs can reduce not just hunger, but the desire to pursue rewarding food,&#8217; he said. &#8216;They\u2019re acting on the system that makes you want the cake, not just the system that makes you feel full.&#8217;<\/p>\n<p class=\"mol-para-with-font\">They also suggested the findings may explain why different drugs within the GLP-1 sphere produce varying side effects like nausea while others do not cause the same level of discomfort.\u00a0<\/p>\n<p class=\"mol-para-with-font\">While most GLP-1s are injectable, pharmaceutical companies like Pfizer and Eli Lilly are racing to come up with cheaper, more appealing oral options. These newer drugs,\u00a0G\u00fcler says, could come with more benefits other than weight loss.\u00a0<\/p>\n<p class=\"mol-para-with-font\">&#8216;If these drugs are affecting reward pathways in the brain, that has implications beyond weight loss,&#8217; he said. &#8216;It could influence things like addiction, impulse control or even how people experience pleasure.<\/p>\n<p class=\"mol-para-with-font\">&#8216;These are powerful compounds.\u00a0We need to understand them fully as they move into everyday use.&#8217;\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>People taking Ozempic and other blockbuster weight loss drugs expect them to curb their appetite and help them lose weight. GLP-1 agonists, which include Ozempic and also Wegovy and Mounjaro, mimic glucagon-like peptide-1 (GLP-1), a naturally present hormone in the gut that slows digestion, regulates blood sugar and tells the body it&#8217;s full &#8211; which<\/p>\n","protected":false},"author":1,"featured_media":9868,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bunyad_sub_title":"","footnotes":""},"categories":[520],"tags":[],"class_list":["post-9867","post","type-post","status-publish","format-standard","has-post-thumbnail","category-hot"],"_links":{"self":[{"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=\/wp\/v2\/posts\/9867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9867"}],"version-history":[{"count":0,"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=\/wp\/v2\/posts\/9867\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=\/wp\/v2\/media\/9868"}],"wp:attachment":[{"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthoptibody.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}